[1]何世勇,温勃阳.沙参麦冬汤联合吉西他滨新辅助化疗、胸腔镜手术治疗早中期肺癌疗效研究[J].陕西中医,2026,(4):492-496.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.011]
　HE Shiyong,WEN Boyang.Efficacy study of Shashen Maidong decoction combined with gemcitabine neoadjuvant chemotherapy and thoracoscopic surgery in the treatment of early- and middle- stage lung cancer[J].,2026,(4):492-496.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.011]
点击复制

沙参麦冬汤联合吉西他滨新辅助化疗、胸腔镜手术治疗早中期肺癌疗效研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年4期
页码:
492-496
栏目:
临床研究
出版日期:
2026-04-05

文章信息/Info

Title:
Efficacy study of Shashen Maidong decoction combined with gemcitabine neoadjuvant chemotherapy and thoracoscopic surgery in the treatment of early- and middle- stage lung cancer
作者:
何世勇; 温勃阳
（北京大学第一医院太原医院胸外科，山西 太原 030000）
Author(s):
HE Shiyong; WEN Boyang
（Department of Thoracic Surgery,Peking University First Hospital Taiyuan Hospital,Taiyuan 030000，China）
关键词:
肺癌; 沙参麦冬汤; 吉西他滨; 免疫功能; 肿瘤标志物; 胸腔镜手术
Keywords:
Lung cancer; Shashen Maidong decoction; Gemcitabine; Immune function; Tumor biomarker; Thoracoscopic surgery
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7369.2026.04.011
文献标志码:
A
摘要:
目的：探究沙参麦冬汤联合吉西他滨新辅助化疗、胸腔镜手术治疗早中期肺癌的疗效及预后。方法：选取82例早中期肺癌患者，随机分为对照组和联合组，每组41例。两组患者均予常规治疗，对照组给予吉西他滨联合胸腔镜手术治疗，联合组在对照组处理基础上给予沙参麦冬汤治疗。两组均连续治疗4周，比较两组患者疗效、术中指标、免疫功能指标、肿瘤标志物水平、KPS评分、血清细胞因子及预后。结果：联合组总有效率高于对照组（χ2=4.556，P<0.05）。两组手术时间、术中出血量、术后下床时间、住院时间、淋巴结清扫个数比较差异有统计学意义（均P＜0.05）。治疗后，两组CD3+、CD4+、CD4+/CD8+、卡氏功能状态（KPS）评分升高，联合组高于对照组（均P<0.05）。治疗后，两组癌胚抗原（CEA）、糖类抗原19-9（CA19-9）、糖类抗原125（CA125）、白细胞介素-10（IL-10）、肿瘤坏死因子-α（TNF-α）降低，联合组低于对照组（均P<0.05）。治疗后，联合组复发率低于对照组，生存率高于对照组（均P<0.05）。两组术后并发症发生率比较差异无统计学意义（χ2=1.406，P>0.05）。结论：沙参麦冬汤联合吉西他滨干预早中期肺癌效果显著，可有效降低患者复发率，提高患者生存率。
Abstract:
Objective:To investigate the efficacy and prognosis of Shashen Maidong decoction combined with gemcitabine neoadjuvant chemotherapy and thoracoscopic surgery in the treatment of early- and middle- stage lung cancer.Methods:Eighty-two patients with early- and middle- stage lung cancer were selected and randomly divided into a control group and a combined group,with 41 patients in each group.All patients in both groups received routine treatment.The control group was treated with gemcitabine combined with thoracoscopic surgery,while the combined group was treated with Shashen Maidong decoction on the basis of the treatment in the control group.Both groups were treated continuously for 4 weeks.The curative effects,intraoperative indicators,immune function indicators,levels of tumor markers,KPS scores,serum cytokines and prognosis of the patients in the two groups were compared before treatment and 4 weeks after treatment.Results:The total effective rate of the combined group was higher than that of the control group (χ2=4.556,P<0.05).There were statistically significant differences in operative time,intraoperative blood loss,time to getting out of bed,length of hospital stay,and number of lymph node dissections between the two groups (all P<0.05).After treatment,CD3+,CD4+,CD4+/CD8+ levels and Karnofsky Performance Status (KPS) scores increased in both groups,and those in the combined group were higher than those in the control group (all P<0.05).After treatment,the levels of carcinoembryonic antigen (CEA),carbohydrate antigen 19-9 (CA19-9),carbohydrate antigen 125 (CA125),interleukin-10 (IL-10),and tumor necrosis factor (TNF-α) decreased in both groups,and those in the combined group were lower than those in the control group (all P<0.05).After treatment,the recurrence rate of the combined group was lower than that of the control group,and the survival rate was higher than that of the control group (all P<0.05).There was no statistically significant difference in the incidence of postoperative complications between the two groups (χ2=1.406,P>0.05).Conclusion:The combination of Shashen Maidong decoction and gemcitabine has a significant effect in the treatment of early- and middle- lung cancer.It can effectively reduce the recurrence rate of patients and improve the survival rate of patients.

参考文献/References:

[1]XU K,ZHANG C,DU T,et al.Progress of exosomes in the diagnosis and treatment of lung cancer[J].Biomed Pharmacother,2021,23(134):111-124.
[2]LAM D C,LIAM C K,ANDARINI S,et al.Lung cancer screening in Asia:An expert consensus report[J].J Thorac Oncol,2023,18(10):1303-1322.
[3]蔺明霞,王俊鹏,崔光彬,等.CT影像学特征联合血清肿瘤特异性标志物检测对肺癌的诊断价值[J].陕西医学杂志,2024,53(12):1673-1675，1684.
[4]姚舒洋,张毅.循环肿瘤DNA监测早期肺癌术后微小残留病灶的研究进展[J].肿瘤学杂志,2023,29(1):66-70.
[5]何纯,刘铮,谭小伟,等.GP新辅助化疗联合手术治疗非小细胞肺癌临床评价[J].中国药业,2022,31(16):86-88.
[6]郭晓黎,任小宁,樊一波,等.沙参麦冬汤通过调节EGFR/MEK/ERK信号通路对非小细胞肺癌细胞增殖、凋亡和自噬的影响[J].中国药师,2022,25(10):1707-1713.
[7]李红珂.益气化瘀汤合沙参麦冬汤辅助化疗治疗气阴两虚型肺癌[J].河南中医,2025，45(7)：1086-1090.
[8]中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2023版)[J].中华肿瘤杂志,2023,45(7):539-574.
[9]徐越,张言斌,苏珊.基于转录组测序探究C-MET表达在非小细胞肺癌中的免疫调控机制[J].实用医学杂志,2024,40(1):7-12.
[10]宋强.低剂量CT扫描联合肿瘤标志物检测对早期肺癌的筛查价值[J].医学影像学杂志,2022,32(9):1507-1520.
[11]乌博莉,韩晓,何春芳.深部热疗对中晚期肺癌患者预后及放射性肺炎的影响[J].癌症进展,2023,21(9):1020-1023.
[12]王永富,吴远林,解少强,等.电视胸腔镜解剖性肺段切除术治疗早期非小细胞肺癌疗效及对血清C-反应蛋白、白细胞介素-1β、白细胞介素-6、肿瘤坏死因子-α水平的影响分析[J].临床外科杂志,2022,30(8):731-734.
[13]李家康,李余发,魏雪武,等.肿瘤细胞和免疫细胞PD-1在早期肺腺癌中的表达及其预后价值[J].循证医学,2022,22(6):364-374.
[14]王园,杨懿,任福强,等.肠道营养干预在中期肺癌患者中应用价值及其对生命质量影响[J].临床军医杂志,2023,51(11):1162-1170.
[15]陆志前,王成林,龙飞翔,等.多层螺旋CT重建在早期肺癌检查中的应用[J].中国CT和MRI杂志,2022,20(5):83-85.
[16]TFAYLI A,ALASSAAD M,FAKHRI G,et al.Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer[J].Cancer Med,2020,9(22):8406-8411.
[17]张毅鹏,张金秋,洪月光.复方苦参注射液联合吉西他滨和顺铂化疗治疗晚期非小细胞肺癌的临床疗效观察[J].北京医学,2023,45(9):799-803.
[18]刘影,熊燕,孟令占,等.沙参麦冬汤加减对肺癌放疗患者生存质量及生存期的影响分析[J].四川中医,2023,41(6):103-106.
[19]杨秋燕,马玉媛,秦悦,等.沙参麦冬汤治疗肺癌药理机制研究进展[J].辽宁中医药大学学报,2024,26(8):173-177.
[20]李佳凝,李佳露,谢钰然.桑叶防治糖尿病的活性成分及其作用机制研究进展[J].陕西中医,2025,46(10):1425-1428.
[21]梁旭睿,黄智,赵卫正.杂交式单操作孔胸腔镜治疗老年早期肺癌的效果及对术后免疫功能的影响分析[J].大医生,2023,8(15):133-136.
[22]钱琳琳,张美伦,马晓北.《温病条辨》中温热类病证用药规律探究[J].陕西中医,2022,43(3):380-383.
[23]李玲.国医大师周仲瑛辨机论治结缔组织病合并间质性肺病的经验探析及前瞻性临床研究[D].南京：南京中医药大学,2020.
[24]阿里甫·依马木,文智,周永,等.高危人群低剂量CT与肿瘤标志物联合检查早期肺癌的效能研究[J].中国CT和MRI杂志,2024,22(2):58-60.
[25]张鹏,李桂香.血清细胞因子表达水平与非小细胞肺癌PD-1抑制剂疗效研究进展[J].兰州大学学报,2024,50(1):82-86.

相似文献/References:

[1]刘海涛 ,衣秀秀,田建辉△.肺癌中西医抗凝治疗研究进展*[J].陕西中医,2020,(1):127.
[2]邵翠丽,周晋华△,杨勤军,等.周晋华运用环磷酰胺联合中药紫杉治疗晚期肺癌经验*[J].陕西中医,2020,(2):223.
　SHAO Cuili,ZHOU Jinhua,YANG Qinjun,et al.ZHOU Jinhua treats advanced lung cancer with cyclophosphamide and purple shirt[J].,2020,(4):223.
[3]汪 莉,杜红旭,周正国,等.攻癌固真汤联合吉非替尼治疗肺癌气虚血瘀证疗效及对患者血流状态的影响[J].陕西中医,2021,(3):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
　WANG Li,DU Hongxu,ZHOU Zhengguo,et al.Clinical effect of Gong'ai Guzhen decoction combined with gefitinib in treating lung cancer with Qixu Xueyu syndrome and affect blood flow state[J].,2021,(4):338.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.017]
[4]郑 茜,刘远婷,丁甜甜,等.消积抑癌方对Lewis肺癌荷瘤小鼠MMP-2的影响[J].陕西中医,2021,(7):844.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
　ZHENG Qian,LIU Yuanting,DING Tiantian,et al.Effect of Xiaoji Yi'ai recipe on MMP-2 in Lewis lung cancer bearing mice[J].,2021,(4):844.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.007]
[5]刘文佳,刘宗凯,初晓苏,等.山慈菇-王不留行干预肺癌向骨转移过程生物信息学作用机制[J].陕西中医,2021,(9):1302.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.041]
[6]杨 昕,李和根.肺癌辨证分型研究进展[J].陕西中医,2021,(9):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
　YANG Xin,LI Hegen.Progress in syndrome differentiation of lung cancer[J].,2021,(4):1313.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.043]
[7]李 健,贾 瑞,王 超,等.健脾益气汤联合化疗对肺癌术后患者免疫功能的影响[J].陕西中医,2023,(4):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
　LI Jian,JIA Rui,WANG Chao,et al.Effect of Jianpi Yiqi decoction combined with chemotherapy on immune function in patients with lung cancer after surgery[J].,2023,(4):459.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.011]
[8]宁永波,王雅兴,陈香颖,等.名中医王瑞平“期证相合”理论在肺癌术后研究肿瘤微环境经验[J].陕西中医,2023,(10):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
　NING Yongbo,WANG Yaxing,CHEN Xiangying,et al.Wang Ruiping's theory of “phase correspondence” in postoperative lung cancer patients[J].,2023,(4):1448.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.026]
[9]张 尤,陈 炜.名中医韩明向基于“一本四证”论治肺癌经验[J].陕西中医,2023,(12):1788.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.027]
[10]陈香颖,宁永波,王雅兴,等.名中医王瑞平运用“培土生金法”治疗肺癌经验[J].陕西中医,2024,(4):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]
　CHEN Xiangying,NING Yongbo,WANG Yaxing,et al.Experience of professor Wang Ruiping using “tonifying the spleen and replenishing the lung” to treat lung cancer[J].,2024,(4):536.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.023]

备注/Memo

备注/Memo:
山西省卫生健康委员会科研项目（2023A117）
更新日期/Last Update: 2026-04-05